Share: Facebook Twitter LinkedIn
Activity Provided By:

i3 Health

Video Viewpoint Strategy Session: New Insights Into Preventing and Managing Chemotherapy-Induced Neutropenia

Access Activity

Overview / Abstract:

Discover recent developments in the prevention, treatment, and management of chemotherapy-induced neutropenia, including a comprehensive understanding of the risk factors and current clinical practice guidelines. This activity is presented by Gary H. Lyman, MD, MPH, FASCO, FACP, FRCP, Professor, University of Washington, and Maura Abbott, PhD, AOCNP®, CPNP, Columbia University School of Nursing. Start the activity now.


Chemotherapy-induced neutropenia (CIN) is a potentially life-threatening toxicity of chemotherapy that has been recognized as a major risk factor for the development of infections in patients with cancer (NCCN, 2021). The severity and duration of neutropenia place patients at higher risk of developing febrile neutropenia (FN) and experiencing dose reductions or delays that may compromise the efficacy of chemotherapy (Gargiulo et al, 2021). Additionally, among patients with cancer, hospitalizations related to complications of CIN result in substantial medical costs, in addition to increased morbidity and mortality (Li et al, 2020). Therefore, it is essential that members of the multidisciplinary team have a comprehensive understanding of the risk factors, current clinical practice guidelines, emerging data, and management strategies for CIN. In this activity, Gary Lyman, MD, MPH, and Maura Abbott, PhD, AOCNP®, CPNP, will update clinicians on recent developments in the prevention, treatment, and management of CIN.


Oncologists, nurse practitioners, physician associates, oncology nurses, and other health care professionals involved in the treatment of patients with chemotherapy-induced neutropenia (CIN).


Upon completion of this activity, participants should be able to

Distinguish patient, tumor, and cancer therapy risk factors for CIN
Evaluate clinical practice guidelines on the management of febrile neutropenia
Assess recent clinical trial findings on novel and emerging agents for CIN prophylaxis and treatment
Apply strategies to prevent and manage infectious complications in patients with CIN


Apr 25, 2023


Nurse Practitioner , Nursing CNE, Pharmacy CPE, Physician CME, Physician Assistant CME


Webinar / Webcast / Video

Credits / Hours

1.0 CME | 1.0 NCPD | MOC | ILNA



Presenters / Authors / Faculty

Gary H. Lyman, MPH, FASCO, FACP, FRCP (Chairperson)
Professor, Public Health Sciences and Clinical Research Divisions
Fred Hutchinson Cancer Research Center
Professor of Medicine, Public Health, Pharmacy
University of Washington

Maura Abbott, PhD, AOCNP®, CPNP
Associate Professor of Nursing
Assistant Dean, Clinical Affairs
Columbia University School of Nursing

Activity Specialities / Related Topics

Oncology / Cancer / Radiation Therapy, Hematology

Sponsors / Supporters / Grant Providers

This activity is supported by an independent educational grant from G1 Therapeutics.

Keywords / Search Terms

i3 Health i3 Health, Chemotherapy-induced neutropenia (CIN), CIN, Neutropenia, Oncology, Supportive Care, online CNE, free CNE, free CE CME, free CE CME, free CE CME, NCPD, free NCPD, online NCPD, online NCPD CME Free CE CME Free CE CME Free CE CME Free CE CME

Access Activity

CORE Higher Education Group,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps.CORE Higher Education Group,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the Terms of Service. Site Map